MA27106A1 - Composition pharmaceutique de chlorhydrate de diltiazem stable pour application cutanee et son procede de preparation - Google Patents

Composition pharmaceutique de chlorhydrate de diltiazem stable pour application cutanee et son procede de preparation

Info

Publication number
MA27106A1
MA27106A1 MA27807A MA27807A MA27106A1 MA 27106 A1 MA27106 A1 MA 27106A1 MA 27807 A MA27807 A MA 27807A MA 27807 A MA27807 A MA 27807A MA 27106 A1 MA27106 A1 MA 27106A1
Authority
MA
Morocco
Prior art keywords
stable
pharmaceutical composition
preparing
same
diltiazem hydrochloride
Prior art date
Application number
MA27807A
Other languages
English (en)
Inventor
Miguel Veiga Abreu R Alexandre
Maria Castro De Abreu Isabel
Original Assignee
Tecnimede Sociedade Tecnico Medicinal Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal Sa filed Critical Tecnimede Sociedade Tecnico Medicinal Sa
Publication of MA27106A1 publication Critical patent/MA27106A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA27807A 2003-09-18 2004-07-29 Composition pharmaceutique de chlorhydrate de diltiazem stable pour application cutanee et son procede de preparation MA27106A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03398006A EP1516622B1 (fr) 2003-09-18 2003-09-18 Composition pharmaceutique stable de chlorhydrate de diltiazem pour application cutanée et procédé pour sa préparation

Publications (1)

Publication Number Publication Date
MA27106A1 true MA27106A1 (fr) 2004-12-20

Family

ID=34178675

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27807A MA27106A1 (fr) 2003-09-18 2004-07-29 Composition pharmaceutique de chlorhydrate de diltiazem stable pour application cutanee et son procede de preparation

Country Status (8)

Country Link
EP (1) EP1516622B1 (fr)
AT (1) ATE376424T1 (fr)
BR (1) BRPI0402223B8 (fr)
DE (1) DE60317063T2 (fr)
ES (1) ES2297111T3 (fr)
MA (1) MA27106A1 (fr)
PT (1) PT1516622E (fr)
TN (1) TNSN04150A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022032A2 (fr) * 2006-08-11 2008-02-21 Solvay Pharmaceuticals, Inc. Compositions pharmaceutiques topiques contenant un bloqueur des canaux calciques et procédé d'utilisation
US10960011B2 (en) 2016-06-23 2021-03-30 Servicio Andaluz De Salud Compositions for the treatment of ischemic ulcers and stretch marks
CN115337258B (zh) * 2022-07-22 2024-10-15 上海奥全生物医药科技有限公司 一种盐酸地尔硫卓的药物组合物、制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
CA2089003C (fr) * 1990-08-13 2001-03-20 David W. Yesair Particules colloidales a base de lipidiques mixtes et de bicarbonate pour l'administration de medicaments ou de calories
KR20020050135A (ko) * 2000-12-20 2002-06-26 조명재 피부 주름 예방 및 완화를 목적으로 하는 피부 외용 조성물

Also Published As

Publication number Publication date
ES2297111T3 (es) 2008-05-01
TNSN04150A1 (fr) 2007-03-12
BRPI0402223B1 (pt) 2016-10-25
BRPI0402223A (pt) 2005-06-07
BRPI0402223B8 (pt) 2021-05-25
EP1516622A1 (fr) 2005-03-23
EP1516622B1 (fr) 2007-10-24
ATE376424T1 (de) 2007-11-15
DE60317063T2 (de) 2008-08-07
PT1516622E (pt) 2008-02-04
DE60317063D1 (de) 2007-12-06

Similar Documents

Publication Publication Date Title
PT1311285E (pt) Composicao farmaceutica liquida contendo um derivado de eritropoietina
IL188506A0 (en) Use of an immunogen for preparation of pharmaceutical composition for treating alzheimer's disease
YU69603A (sh) Atorvastatin kalcijum u farmaceutskom obliku, njegovoj smeši i farmaceutskoj formulaciji, koja sadrži atorvastatin kalcijum
HU0303037D0 (en) Compounds to treat alzheimer's disease and pharmaceutical compositions containing them
GB0100758D0 (en) Immunogenic complex method of preparation thereof and pharmaceutical compositions containing the same, useful for disease control
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
BRPI0407181A (pt) Formulação farmacêutica
UY27548A1 (es) Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas
BR9909958A (pt) Formulação farmacêutica, respectivos processo de preparação e uso e método de tratamento ou prevenção de distúrbios ósseos
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
HUP0100024A3 (en) Pharmaceutical compositions for treating alzheimer's disease containing carvedilol as active ingredient
EP1539718A4 (fr) Derive de 1,2,4-triazole, son procede de preparation et composition pharmaceutique le contenant
MXPA04005552A (es) Analogos de vitamina d.
MA27106A1 (fr) Composition pharmaceutique de chlorhydrate de diltiazem stable pour application cutanee et son procede de preparation
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
SE0202692D0 (sv) Compounds
PT1406859E (pt) Derivados substituídos de 4-aminociclo-hexanol
FR2851734B1 (fr) Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
AU2002223170A1 (en) Pharmaceutical composition and method for treatment of brain injury, spinal cord injury, stroke, neurodegenerative disease and other conditions
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
HUP0402417A3 (en) N,n'-disubstituted piperazine compounds process for producing them, pharmaceutical compositions containing them and use thereof
DE50212538D1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzoäcüfluoren-6-carbonsäurederivate als nmda-antagonisten
AU2001255234A1 (en) Cellular calcium responce for diagnosis of alzheimer's disease
HUP0402418A3 (en) Substituted 1,5-diaminopentan-3-ol compounds, process for producing them, pharmaceutical compositions containing them and use thereof